Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Bevacizumab

EU orphan designation number: EU/3/14/1390   
Active ingredient: Bevacizumab
Indication: Treatment of hereditary haemorrhagic telangiectasia
Sponsor: Dr Sophie Dupuis-Girod
Femme Mère Enfant Hospital, Batiment A1 - HHT reference Center, 59 bd Pinel, 69677 Bron Cedex, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/12/2014 Orphan designation EMA/OD/167/14 (2014)10038 of 16/12/2014